Arcoma AB
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanc… Read more
Arcoma AB (ARCOMA) - Net Assets
Latest net assets as of September 2025: Skr73.39 Million SEK
Based on the latest financial reports, Arcoma AB (ARCOMA) has net assets worth Skr73.39 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr97.97 Million) and total liabilities (Skr24.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr73.39 Million |
| % of Total Assets | 74.91% |
| Annual Growth Rate | 7.78% |
| 5-Year Change | 19.79% |
| 10-Year Change | 18.87% |
| Growth Volatility | 67.35 |
Arcoma AB - Net Assets Trend (2012–2024)
This chart illustrates how Arcoma AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arcoma AB (2012–2024)
The table below shows the annual net assets of Arcoma AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr59.33 Million | +21.94% |
| 2023-12-31 | Skr48.66 Million | +6.06% |
| 2022-12-31 | Skr45.88 Million | +4.17% |
| 2021-12-31 | Skr44.04 Million | -11.09% |
| 2020-12-31 | Skr49.53 Million | +9.62% |
| 2019-12-31 | Skr45.19 Million | +15.76% |
| 2018-12-31 | Skr39.03 Million | -4.41% |
| 2017-12-31 | Skr40.83 Million | +9.33% |
| 2016-12-31 | Skr37.35 Million | -25.18% |
| 2015-12-31 | Skr49.92 Million | +19.62% |
| 2014-12-31 | Skr41.73 Million | +233.32% |
| 2013-12-31 | Skr12.52 Million | -48.15% |
| 2012-12-31 | Skr24.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcoma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 116.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr32.96 Million | 55.55% |
| Common Stock | Skr26.37 Million | 44.45% |
| Other Comprehensive Income | Skr29.22 Million | 49.24% |
| Total Equity | Skr59.33 Million | 100.00% |
Arcoma AB Competitors by Market Cap
The table below lists competitors of Arcoma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ashima Limited
NSE:ASHIMASYN
|
$8.53 Million |
|
WMG Holdings Bhd
KLSE:6378
|
$8.54 Million |
|
Retractable Technologies Inc
NYSE MKT:RVP
|
$8.55 Million |
|
Sensen Networks Ltd
AU:SNS
|
$8.55 Million |
|
Equatorial Resources Ltd
AU:EQX
|
$8.53 Million |
|
Knight Club Capital Asset Management PCL
BK:KCC
|
$8.53 Million |
|
Duong Hieu Trading and Mining JSC
VN:DHM
|
$8.52 Million |
|
SCAND.INV.GR.NAM.B DK 05
F:2D2
|
$8.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcoma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,657,000 to 59,334,000, a change of 10,677,000 (21.9%).
- Net income of 11,179,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 10,677,001.
- Other factors decreased equity by 11,179,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr11.18 Million | +18.84% |
| Other Comprehensive Income | Skr10.68 Million | +17.99% |
| Other Changes | Skr-11.18 Million | -18.84% |
| Total Change | Skr- | 21.94% |
Book Value vs Market Value Analysis
This analysis compares Arcoma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 28.80x to 1.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.28 | Skr8.02 | x |
| 2013-12-31 | Skr0.14 | Skr8.02 | x |
| 2014-12-31 | Skr0.86 | Skr8.02 | x |
| 2015-12-31 | Skr4.80 | Skr8.02 | x |
| 2016-12-31 | Skr3.61 | Skr8.02 | x |
| 2017-12-31 | Skr3.50 | Skr8.02 | x |
| 2018-12-31 | Skr3.09 | Skr8.02 | x |
| 2019-12-31 | Skr3.57 | Skr8.02 | x |
| 2020-12-31 | Skr3.89 | Skr8.02 | x |
| 2021-12-31 | Skr3.40 | Skr8.02 | x |
| 2022-12-31 | Skr3.51 | Skr8.02 | x |
| 2023-12-31 | Skr3.65 | Skr8.02 | x |
| 2024-12-31 | Skr4.50 | Skr8.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcoma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.84%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.13%
- • Asset Turnover: 1.95x
- • Equity Multiplier: 1.36x
- Recent ROE (18.84%) is above the historical average (-11.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -13.36% | -2.19% | 2.16x | 2.84x | Skr-5.64 Million |
| 2013 | -92.85% | -11.47% | 1.43x | 5.66x | Skr-12.88 Million |
| 2014 | 2.19% | 0.70% | 1.65x | 1.90x | Skr-3.26 Million |
| 2015 | -12.92% | -5.23% | 1.46x | 1.69x | Skr-11.44 Million |
| 2016 | -31.18% | -11.41% | 1.43x | 1.91x | Skr-15.38 Million |
| 2017 | -24.05% | -10.69% | 1.35x | 1.67x | Skr-13.90 Million |
| 2018 | -4.06% | -1.33% | 1.57x | 1.95x | Skr-5.49 Million |
| 2019 | 14.63% | 4.94% | 1.60x | 1.84x | Skr2.09 Million |
| 2020 | 2.76% | 1.16% | 1.24x | 1.92x | Skr-3.59 Million |
| 2021 | -16.97% | -6.38% | 1.48x | 1.80x | Skr-11.88 Million |
| 2022 | 4.15% | 1.52% | 1.25x | 2.19x | Skr-2.69 Million |
| 2023 | 5.27% | 1.57% | 1.99x | 1.68x | Skr-2.30 Million |
| 2024 | 18.84% | 7.13% | 1.95x | 1.36x | Skr5.25 Million |
Industry Comparison
This section compares Arcoma AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $178,076,436
- Average return on equity (ROE) among peers: -126.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcoma AB (ARCOMA) | Skr73.39 Million | -13.36% | 0.33x | $8.53 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $28.01 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $328.34 Million | -9.08% | 1.00x | $19.50 Million |
| CellaVision AB (CEVI) | $815.73 Million | 17.25% | 0.24x | $265.75 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $21.18 Million | -300.30% | 2.15x | $13.01 Million |
| Chordate Medical Holding AB (CMH) | $10.98 Million | -226.67% | 0.72x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $347.20 Million | 3.02% | 0.44x | $56.12 Million |
| Duearity AB (DEAR) | $11.04 Million | -140.58% | 0.46x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $759.76K | -71.11% | 0.59x | $5.40 Million |